trending Market Intelligence /marketintelligence/en/news-insights/trending/JUn4F2mqWjNm-kbHjkKuPg2 content esgSubNav
In This List

HHS division, Cytori execute $13.4M contract option

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


HHS division, Cytori execute $13.4M contract option

The Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, signed a contract option valued at about $13.4 million with Cytori Therapeutics Inc.

The executed option will fund Cytori's clinical trial of Cytori Cell Therapy to develop it as a medical countermeasure for thermal burn injury.

According to the company, the contract option increases the authority's overall commitment to Cytori technology to about $34.6 million.

The original contract retains two as-yet unfunded options valued at up to $68 million. The first option is written to support a clinical trial that could potentially follow the present clinical trial on Cytori Cell Therapy and lead to its U.S. FDA approval as a treatment for thermal burn injury.

The second option addresses additional preclinical work targeting application in thermal burn and radiation injury.